Patient-derived xenografts and organoids model therapy response in prostate cancer

Patient-derived xenografts and organoids model therapy response in prostate cancer

To date, patients still succumb to cancer, due to tumors not responding to therapy or ultimately acquiring resistance. Here the authors show that by exploiting patient derived organoids and a treatment-naïve patient derived xenograft, patient therapy can be personalized.

Bibliographic Details
Main Authors: Sofia Karkampouna, Federico La Manna, Andrej Benjak, Mirjam Kiener, Marta De Menna, Eugenio Zoni, Joël Grosjean, Irena Klima, Andrea Garofoli, Marco Bolis, Arianna Vallerga, Jean-Philippe Theurillat, Maria R. De Filippo, Vera Genitsch, David Keller, Tijmen H. Booij, Christian U. Stirnimann, Kenneth Eng, Andrea Sboner, Charlotte K. Y. Ng, Salvatore Piscuoglio, Peter C. Gray, Martin Spahn, Mark A. Rubin, George N. Thalmann, Marianna Kruithof-de Julio
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-21300-6

Internet

https://doi.org/10.1038/s41467-021-21300-6

Similar Items